# A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG1101 )

> **NCT07032324** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Qian Wenbin** · enrollment: 27 (estimated)

## Conditions studied

- B-Cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** CAR T cells

## Key facts

- **NCT ID:** NCT07032324
- **Lead sponsor:** Qian Wenbin
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-08
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2025-06-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07032324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07032324, "A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG1101 )". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07032324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*